These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9343288)

  • 21. Sural nerve lesions in a case of hypertyrosinemia.
    Origuchi Y; Endo F; Kitano A; Nagata N; Matsuda I
    Brain Dev; 1982; 4(6):463-8. PubMed ID: 7168483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoimmune thyroiditis in a case of tyrosinaemia type III.
    D'Eufemia P; Giardini O; Cantani A; Martino F; Finocchiaro R
    J Inherit Metab Dis; 1992; 15(6):861-2. PubMed ID: 1293381
    [No Abstract]   [Full Text] [Related]  

  • 23. Tyrosinemia without liver or renal damage with plantar and palmar keratosis and keratitis (hypertyrosinemia type II).
    Pelet B; Antener I; Faggioni R; Spahr A; Gautier E
    Helv Paediatr Acta; 1979 May; 34(2):177-83. PubMed ID: 156708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incurable keratitis and chronic palmoplantar hyperkeratosis with hypertyrosinemia. Cure using a tyrosine-restricted diet. Type II tyrosinemia].
    Hervé F; Moreno JL; Ogier H; Saudubray JM; De Prost Y; Duffier JL; Charpentier C; Lemonnier F; Frézal J
    Arch Fr Pediatr; 1986 Jan; 43(1):19-22. PubMed ID: 2939812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological abnormalities in a patient with tyrosinaemia type III.
    D'Eufemia PD; Finocchiaro R; Celli M; Viozzi L; Giardini O
    J Inherit Metab Dis; 1995; 18(3):355-6. PubMed ID: 7474904
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement.
    Giardini O; Cantani A; Kennaway NG; D'Eufemia P
    Pediatr Res; 1983 Jan; 17(1):25-9. PubMed ID: 6132360
    [No Abstract]   [Full Text] [Related]  

  • 27. Diagnosis and management of tyrosinemia type I.
    Holme E; Lindstedt S
    Curr Opin Pediatr; 1995 Dec; 7(6):726-32. PubMed ID: 8776026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary p-tyramine in hereditary tyrosinemia: II. Origin of urinary p-tyramine.
    Hoag GN; Hill A; Zaleski W
    Clin Biochem; 1977 Feb; 10(1):26-8. PubMed ID: 837523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia.
    Berger R; van Faassen H; Smith GP
    Clin Chim Acta; 1983 Oct; 134(1-2):129-41. PubMed ID: 6652907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Painful keratoderma and photophobia: hallmarks of tyrosinemia type II.
    Rabinowitz LG; Williams LR; Anderson CE; Mazur A; Kaplan P
    J Pediatr; 1995 Feb; 126(2):266-9. PubMed ID: 7844676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of tyrosinaemia type III.
    Ellaway CJ; Holme E; Standing S; Preece MA; Green A; Ploechl E; Ugarte M; Trefz FK; Leonard JV
    J Inherit Metab Dis; 2001 Dec; 24(8):824-32. PubMed ID: 11916315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Association, in the same subject, of deletion of the short arm of chromosome 4 (4p-) and of complete deficiency of parahydroxyphenyl-pyruvate oxidase activity in the liver (tyrosinosis)].
    Malpuech G; Mattei JF; Gaulme J; Palcoux JB; Lesec G; Vanlieferinghen P
    J Genet Hum; 1981 Dec; 29(4):455-61. PubMed ID: 7328420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benign tyrosinaemia: an 18-year follow-up.
    Stoppoloni G; Santinelli R; Prisco F; Canino G; Iafusco D; Di Palma F
    J Inherit Metab Dis; 1995; 18(5):641-2. PubMed ID: 8598649
    [No Abstract]   [Full Text] [Related]  

  • 34. Metabolic studies on two patients with nonhepatic tyrosinemia using deuterated tyrosine loads.
    Faull KF; Gan I; Halpern B; Hammond J; Im S; Cotton RG; Danks DM; Freeman R
    Pediatr Res; 1977 May; 11(5):631-7. PubMed ID: 870870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation.
    Najafi R; Mostofizadeh N; Hashemipour M
    Adv Biomed Res; 2018; 7():7. PubMed ID: 29456978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
    Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
    Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.
    Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK
    Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosinemia Type III detected via neonatal screening: management and outcome.
    Heylen E; Scherer G; Vincent MF; Marie S; Fischer J; Nassogne MC
    Mol Genet Metab; 2012 Nov; 107(3):605-7. PubMed ID: 23036342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow up of a new case of hawkinsinuria.
    Lehnert W; Stögmann W; Engelke U; Wevers RA; van den Berg GB
    Eur J Pediatr; 1999 Jul; 158(7):578-82. PubMed ID: 10412819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The metabolic basis of the hyperphenylalaninemias and tyrosinemia].
    Shintaku H
    Nihon Rinsho; 1992 Jul; 50(7):1542-7. PubMed ID: 1357201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.